Communiqués Moderna, Inc.

Actions

MRNA

US60770K1079

Produits pharmaceutiques

Marché Fermé - 22:00:00 27/08/2026 Pré-ouverture 13:49:04
142,77 USD -4,60% Graphique intraday de Moderna, Inc. 144,45 +1,18%

Communiqués

13:00 Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes AQ
27/08 Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines AQ
27/08 Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes AQ
06/08 Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA AQ
04/08 Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus AQ
31/07 Moderna: Q2 Earnings Snapshot AQ
31/07 Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates AQ
16/07 Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors AQ
09/07 Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 AQ
08/07 Moderna Appoints Michael McDonnell to Board of Directors AQ
25/06 Moderna Science Day Highlights Expanding Potential of mRNA Platform AQ
18/06 Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine AQ
17/06 Moderna to Host Investor Event - Science Day AQ
16/06 Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028 AQ
09/06 Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome AQ
02/06 Moderna to Present at Upcoming Conference in June 2026 AQ
01/06 Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus AQ
12/05 Moderna Recognized by TIME as One of the World's Most Impactful Companies AQ
06/05 Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 AQ
04/05 Moderna : Presentation (Moderna 1Q26 Earnings Presentation FINAL) PU
01/05 Moderna : Transcript (MRNA USQ Transcript 2026 05 01 1) PU
01/05 Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL) PU
01/05 Moderna: Q1 Earnings Snapshot AQ
01/05 Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates AQ
22/04 Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines) PU
Aucun résultat pour cette recherche